1 of 18

Emily Fox, Ava Kosinski, Chloe Mobley, Emma Niszczak, Amy Rodriguez, and Ted Sherman

ES395

epimonitor

epilepsy monitor

2 of 18

Emily Fox

Psychology Major

Business Minor

epimonitor team

Ava Kosinski

Business and

Design Dual Major

Chloe Mobley

Communications Major

Business Minor

Emma Niszczak

Microbiology Major

Business Minor

Amy Rodriguez

Design/Anthropology

Business Minor

Ted Sherman

Political Science Major

Business Minor

3 of 18

Real-time drug monitoring for epilepsy patients using a wearable biosensor device

Continuously measures anticonvulsant medications in the bloodstream and alerts patients before levels drop too low

Personalized sensing technology calibrated to specific seizure medications like Keppra or Lamictal

What We Do

epimonitor

4 of 18

Bridges the gap between dosing and breakthrough seizures by providing data that traditional lab tests can’t offer

Company Description

Empowers patients and clinicians with accurate, on-demand insights to improve medication adherence and outcomes

epimonitor

5 of 18

Product Description

epimonitor

6 of 18

Product Features

epimonitor

01

We provide a dedicated profile section to help you manage your epilepsy, track changes in your health, and monitor important blood levels for better care.

HEALTH METRICS

02

Stay on top of your treatment with our medication reminders. Set personalized alerts to ensure you take your anti-epileptic medications on time.

MEDICATION REMINDERS

03

Access reliable, easy to read resources in our Education Hub. Learn about epilepsy, treatment options, lifestyle tips, and ways to live.

EDUCATION HUB

7 of 18

Product/Service Design

Accessibility and functionality is our priority. Epimonitor keeps you connected on mobile, desktop, and wearable devices.

epimonitor

Wearable Technology

Desktop Mode

8 of 18

Market Analysis

Projected growth for epilepsy monitoring devices
The Americas hold 45.21% of the market, Europe & Australia holds 30.88% and Asia holds 23.92%
3,538,638 active cases of epilepsy in the U.S. in 2021

11.5% of cases are children
90% of epileptic patients take seizure medication

2021

$482.9 M

2027

$637.8 M

epimonitor

9 of 18

Competition

Empatica

only FDA-approved seizure monitoring device

Epilert

wearable for seizure monitoring

Lifelines Neuro Co.

at-home epilepsy diagnosis

Emotiv

at-home EEG for seizure monitoring

Smart Monitor

detects and alerts possible seizures using existing Apple Watch technology

epimonitor

10 of 18

S

W

T

W

O

Novel monitoring technology
High impact, necessary product

Government regulations

FDA

Existing patents
Extended time for product development

Expand technology to monitor levels of other drugs

Existing wearable devices for seizure monitoring
New epilepsy treatments

epimonitor

11 of 18

epimonitor

Lorem ipsum

Dolor nec

Ipsum dolor amet dolor

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

1

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

2

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

3

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum

Dolor nec

Ipsum dolor amet dolor

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

1

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

2

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

3

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum

Dolor nec

Ipsum dolor amet dolor

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

TikTok

Instagram

1

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

2

Lorem ipsum dolor sit amet nec at adipiscing

Lorem ipsum dolor sit
amet nec at adipiscing
risus at dolor porta

3

Lorem ipsum dolor sit amet nec at adipiscing

4

Lorem ipsum dolor sit amet nec at adipiscing

Income

Promotional

Demand

Age

**

$

1

13-22

***

$$

Instagram

Youtube

2

23-35

****

$$$

Email

Doctor Referral

3

36-55

****

$$$$

Healthcare providers

Clinics

4

56+

Dolor nec

Price

$600

$700

$800

Marketing Strategy

Consumer Segmentation

12 of 18

Target Market

epimonitor

Manage epilepsy independently
Prioritize health and safety
High income, purchasing power
Trust in medical professionals

Adults aged 36-55

Peace of mind, independence, and confidence in managing their condition

13 of 18

Operations

The business will be based in Boston, Massachusetts

Access to leading medical institutions, research universities, and talent
Proximity to many FDA consultants and testing facilities

The Boston facility will serve as a central hub for operations, research, and quality control
Our product distribution process will use a hybrid model that includes both B2B and B2C aspects

Direct sales to hospitals and clinics
Partnerships with medical device distributors
Direct to consumer

epimonitor

14 of 18

Financials

Snapshot & Investor Returns

epimonitor

Years After Launch	Revenue	EBITDA
Year 1	$3 M	($4 M)
Year 2	$12 M	($1 M)
Year 3	$35 M	$10 M

Break-even: Year 3 after FDA clearance

Profitability: Year 3 onward

Investor Exit: Target Year 7, at 4–6× revenue (based on CGM / digital neurology comps)

Because this is a medical device, the financials are not about overnight growth, we don’t expect meaningful revenue until after FDA clearance.

Once we launch, we’re assuming a subscription-style model at about one hundred fifty dollars per patient per month, which includes the device, sensors, and software.

That gets us to roughly three million in revenue in our first year post-launch, twelve million in year two, and about thirty-five million by year three.

year three revenue still represents less than two percent of the global epilepsy device market, so we are not assuming aggressive penetration.

We break even around year three as fixed R&D and regulatory costs stop growing and operating leverage kicks in. For investors, that creates a realistic exit window around years six to eight through acquisition or sustained cash flow, similar to other monitoring device companies

15 of 18

Funding

epimonitor

Total Capital Required: ~$18–22M Pre-Commercialization

Targeting:

Healthcare-focused VC

Health & MedTech angel investors

University-affiliated research funds

Grants (NSF, NIH)

Seed Round: $3–4M

�Series A: $7-9M

Series B: $8-9M

16 of 18

Risks

R&D complexity

Manufacturing Scalability

FDA

Requirements

User

Adoption

Data

Privacy

epimonitor

Clinical Validation

17 of 18

Timeline

2030

Clinical Trials & Regulatory Preparation

Validate device accuracy against standard blood tests across daily living conditions
Finalize hardware, algorithm calibration, and safety data
Prepare and submit FDA regulatory pathway package

2032

Market Launch & Scaling

Launch first commercial model supporting the top anticonvulsant medications
Partner with neurologists, clinics, and hospitals for distributions
Scale manufacturing, explore insurance reimbursement, and expand globally

2026

Concept Validation & Feasibility

Establish scientific feasibility of real-time anticonvulsant detection using biosensors
Build initial benchtop prototypes and conduct in-vitro tests with simulated plasma

2028

Prototype Development & Preclinical Testing

Create the first wearable prototype integrating the biosensor
Build early software and alert system
Conduct lab performance testing and early preclinical validation
File patents and begin FDA pre-submission consultations

epimonitor

18 of 18

Thank You!

Questions?

epimonitor